Quick Answer
CytoDyn Inc. reported Net Income Loss of $3.75 million for the year ending 2025.
- CytoDyn Inc. showed an increase of +107.5% in Net Income Loss from 2024 to 2025.
- This data is from CytoDyn Inc.'s annual report (Form 10-K), filed with the SEC on July 25, 2025.
- XBRL data for this metric is available from 2005 to 2025 (21 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 21 years of available data (2005 to 2025), CytoDyn Inc.'s Net Income Loss has grown by 581.9%.
- Historical annual values: Fiscal year 2025: $3.75 million | Fiscal year 2024: -$49.84 million | Fiscal year 2023: -$79.82 million | Fiscal year 2022: -$210.82 million | Fiscal year 2021: -$176.47 million | Fiscal year 2020: -$139.94 million | Fiscal year 2019: -$56.19 million | Fiscal year 2018: -$50.15 million | Fiscal year 2017: -$25.76 million | Fiscal year 2016: -$25.70 million | Fiscal year 2015: -$25.09 million | Fiscal year 2014: -$12.43 million | Fiscal year 2013: -$9.57 million | Fiscal year 2012: -$7.47 million | Fiscal year 2011: -$3.72 million | Fiscal year 2010: -$3.36 million | Fiscal year 2009: -$1.31 million | Fiscal year 2008: -$1.19 million | Fiscal year 2007: -$2.61 million | Fiscal year 2006: -$2.05 million | Fiscal year 2005: -$777.1 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: